Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $143.5 million.

  • Seres Therapeutics' Liabilities and Shareholders Equity fell 1973.18% to $143.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $591.3 million, marking a year-over-year decrease of 5074.17%. This contributed to the annual value of $139.8 million for FY2024, which is 6101.23% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Liabilities and Shareholders Equity is $143.5 million, which was down 1973.18% from $143.8 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Liabilities and Shareholders Equity registered a high of $406.4 million during Q2 2023, and its lowest value of $139.8 million during Q4 2024.
  • Its 5-year average for Liabilities and Shareholders Equity is $285.1 million, with a median of $311.9 million in 2022.
  • Per our database at Business Quant, Seres Therapeutics' Liabilities and Shareholders Equity skyrocketed by 17634.95% in 2021 and then tumbled by 6101.23% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Liabilities and Shareholders Equity stood at $354.9 million in 2021, then decreased by 1.71% to $348.8 million in 2022, then increased by 2.81% to $358.6 million in 2023, then plummeted by 61.01% to $139.8 million in 2024, then rose by 2.62% to $143.5 million in 2025.
  • Its last three reported values are $143.5 million in Q3 2025, $143.8 million for Q2 2025, and $164.2 million during Q1 2025.